Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dofetilide: a class III-specific antiarrhythmic agent.

J S Kalus1, V F Mauro

  • 1College of Pharmacy, University of Toledo, OH 43606, USA.

The Annals of Pharmacotherapy
|February 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.

Diabetic medicine : a journal of the British Diabetic Association·2007
Same author

Enoxaparin should be used cautiously in patients with end-stage renal disease.

Pharmacotherapy·2001
Same author

A comprehensive review of antihypertensive agents providing renal protection.

Connecticut medicine·2001
Same author

New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.

The Annals of pharmacotherapy·2001
Same author

Calcium-channel antagonists and nitrates in coronary artery bypass patients receiving radial artery grafts.

The Annals of pharmacotherapy·2001
Same author

Impact of oral bases on aluminum absorption.

American journal of therapeutics·2001
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Dofetilide is a Class III antiarrhythmic drug effective for atrial dysrhythmias. While promising for heart failure, its proarrhythmic potential, particularly torsade de pointes, requires further study.

Area of Science:

  • Pharmacology
  • Cardiology

Background:

  • Cardiac dysrhythmias present a significant clinical challenge.
  • Antiarrhythmic drug development aims to improve efficacy and safety.

Purpose of the Study:

  • To review the pharmacology and clinical applications of dofetilide for cardiac dysrhythmias.
  • To assess dofetilide's potential role in managing atrial and ventricular arrhythmias and heart failure.

Main Methods:

  • A comprehensive MEDLINE search (1966-1999) was conducted using "dofetilide" and "UK-68,798".
  • English-language articles and relevant abstracts were reviewed for pharmacological and clinical data.

Main Results:

  • Dofetilide is a specific Class III antiarrhythmic agent that prolongs action potential duration and effective refractory period by blocking potassium efflux.

Related Experiment Videos

  • It shows potential in treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, and preventing ventricular tachycardia.
  • Preliminary data suggest benefits in heart failure patients, but a significant risk of proarrhythmias, especially torsade de pointes, exists.

    • Conclusions:

    • Dofetilide demonstrates a role in the pharmacotherapy of cardiac dysrhythmias, particularly those of atrial origin.
    • Further research is necessary to fully establish its efficacy and tolerability compared to existing antiarrhythmic agents.